Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SI | P14410 | 2/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734163 | 0.81 | PTPN1 (0.37) | PTPN1IKBKBRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL3739137 | 0.80 | HSD17B10 (0.38) | PTPN1GAAMAOBALDH1A1TDP1 | |
| SCHEMBL3727477 | 0.80 | PTPN1 (0.38) | PTPN1F2RL3GAAL3MBTL1ALDH1A1 | |
| SCHEMBL3734730 | 0.77 | PTPN1 (0.41) | PTPN1F2RL3HSD11B1 | |
| SCHEMBL3737667 | 0.76 | ASIC3 (0.40) | GAAALDH1A1MEN1RAB9AKMT2A | |
| SCHEMBL4374306 | 0.75 | DHFR (0.41) | ALDH1A1HPGDADORA1 | |
| SCHEMBL3742648 | 0.72 | PTPN1 (0.38) | PTPN1 | |
| SCHEMBL4380468 | 0.71 | PTPN1 (0.40) | PTPN1ALDH1A1 | |
| SCHEMBL4528842 | 0.70 | LMNA (0.37) | L3MBTL1ALDH1A1TDP1MEN1RAB9A | |
| SCHEMBL3742273 | 0.69 | PTPN1 (0.36) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910359-B1 | PYRIDO [2 , 3-D]PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | EP | claimed |
| EP-1910359-A1 | PYRIDO [2 , 3-D]PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | F. Hoffmann-Roche AG (CH) | 2008-04-16 | — | — | EP | claimed |
| WO-2007009911-A1 | PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | claimed |
| US-20100280021-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | BERTHEL STEVEN JOSEPH | 2010-11-04 | — | — | US | disclosed |
| EP-1910359-B1 | PYRIDO [2 , 3-D]PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-20090062276-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | BERTHEL STEVEN JOSEPH | 2009-03-05 | — | — | US | disclosed |
| EP-1910359-A1 | PYRIDO [2 , 3-D]PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | F. Hoffmann-Roche AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009911-A1 | PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021445-A1 | Pyridopyrimidine protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062276-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PTPRF, PTPN1, PTPRCAP | PTPN1 2/4885F2RL3 3980/4885GSK3B 139/4885 |
| US-20070021445-A1 | Pyridopyrimidine protein tyrosine phosphatase inhibitors | PTPRF, PTPN1, PTPRCAP | PTPN1 2/4885F2RL3 3980/4885GSK3B 139/4885 |
| US-20100280021-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PTPRF, PTPN1, PTPRCAP | PTPN1 2/4885F2RL3 3980/4885GSK3B 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.